Your Search Returned 45 tagged news reports
ET A pain drug developed by Endo Pharmaceuticals PLC and BioDelivery Sciences International Inc. met its primary endpoint in a Phase 3 study, the companies said Monday. Shares of BioDelivery Sciences jumped 22% to $14.60 in premarket trading as the
Portfolio of Asana includes multiple compounds for oncology and pain indications that are ready to enter clinical trials. Asana chief executive officer Sandeep Gupta said the company's mission is to develop new and clinically differentiated products
US Food and Drug Administration (FDA) for Frovatriptan Succinate Tablets, 2.5mg.
The Record New Jersey will receive $3.1 million as part of a multi-state settlement with a Pennsylvania-based pharmaceutical company that allegedly used unlawful marketing practices to promote a drug for uses not approved by the federal Food and Drug
S Global pharmaceutical company Galen has acquired exclusive US rights to market and sell Nuvo's Synera, a topical patch that combines lidocaine, tetracaine and heat. The FDA approved patch is currently indicated to provide local dermal analgesia for
Opioid drug sales increased 110 percent between 2001 and 2012, while overdose deaths from prescription opioids more than quadrupled from 1999 to 2010, the New York Times recently reported. Two lawmakers on the House Energy and Commerce Subcommittee
S&P Biotech Index up 38% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies that made waves in
According to the Organic Trade Association industry survey for 2011, organic food sales grew about 13.4% annually from 2002 to 2010, while conventional food sales remained largely flat. That kind of growth is about in line with that of Whole Foods,
District Court in New Jersey, saying Endo's sales of Opana ER, a formulation of oxymorphone hydrochloride, violate three Depomed patents.
Aeropostale (ARO) was downgraded by Keybanc (KEY) to hold from buy as the middle income consumer remains under financial pressure...Piper Jaffray (PJC) to underweight from neutral with a price target of $22 due a uncertain outlook for generic drugs.